Roth Capital Reiterates Positive Rating for Infinity Pharmaceuticals (INFI)
A number of other analysts have also recently weighed in on INFI. Analysts at Wedbush upgraded shares of Infinity Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Wednesday. They now have a $15.00 price target on the stock, up previously from $9.00. Separately, analysts at William Blair upgraded shares of Infinity Pharmaceuticals to an “outperform” rating in a research note on Wednesday, August 6th. Finally, analysts at Morgan Stanley initiated coverage on shares of Infinity Pharmaceuticals in a research note on Wednesday, June 25th. They set an “overweight” rating and a $17.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Infinity Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $17.38.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) traded up 52.84% during mid-day trading on Wednesday, hitting $16.69. 13,951,982 shares of the company’s stock traded hands. Infinity Pharmaceuticals has a 52 week low of $8.40 and a 52 week high of $21.60. The stock’s 50-day moving average is $10.43 and its 200-day moving average is $11.30. The company’s market cap is $810.9 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, August 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06. During the same quarter in the previous year, the company posted ($0.68) earnings per share. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Infinity Pharmaceuticals will post $-3.48 earnings per share for the current fiscal year.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.